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Abstract
Human respiratory syncytial virus (HRSV) is an important respiratory pathogen primarily affecting
infants, young children, transplant recipients and the elderly. The F protein is the only virion
envelope protein necessary and sufficient for virus replication and fusion of the viral envelope
membrane with the target host cell. During natural infection, HRSV replication is limited to
respiratory epithelial cells with disseminated infection rarely, if ever, occurring even in
immunocompromised patients. However, in vitro infection of multiple human and non-human cell
types other than those of pulmonary tract origin has been reported. To better define host cell
surface molecules that mediate viral entry and dissect the factors controlling permissivity for HRSV,
we explored the host range of HRSV F protein mediated fusion. Using a novel recombinant
reporter gene based fusion assay, HRSV F protein was shown to mediate fusion with cells derived
from a wide range of vertebrate species including human, feline, equine, canine, bat, rodent, avian,
porcine and even amphibian (Xenopus). That finding was extended using a recombinant HRSV
engineered to express green fluorescent protein (GFP), to confirm that viral mRNA expression is
limited in several cell types. These findings suggest that HRSV F protein interacts with either highly
conserved host cell surface molecules or can use multiple mechanisms to enter cells, and that the
primary determinants of HRSV host range are at steps post-entry.
Background
Human respiratory syncytial virus (HRSV) is the single
most common cause of serious lower respiratory tract
infections (LRTIs) in infants and young children causing
up to 126,000 hospitalizations annually in the U.S. [1]
with an estimated 500 deaths per year [2]. HRSV bronchi-
olitis has been associated with the development and exac-
erbation of wheezing and other respiratory conditions.
Furthermore, HRSV is an increasingly recognized cause of
pneumonia, exacerbation of chronic pulmonary and car-
diac disease, and death in the elderly [3]. HRSV is also the
most common viral respiratory infection of transplant
recipients and is responsible for high rates of mortality in
this group [4].
HRSV is member of the subfamily Pneumovirinae in the
Paramyxoviridae family [5]. Two serologic subgroups (A
and B) have been described and co-circulate throughout
the world. Three viral transmembrane proteins (G, SH
and F) are found on surface of the virus particle in the viral
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envelope. The G protein is a heavily glycosylated protein
that mediates attachment of the virus to host cells, and
although not strictly required for virus replication in cul-
ture, recombinant viruses lacking the G protein are atten-
uated in animals [6,7]. While its exact function is
unknown, the SH gene is not essential for virus growth in
tissue culture, and its deletion only results in slight atten-
uation in animals [6,8-12]. The F protein is a type 1 mem-
brane protein essential for the packaging and formation of
infectious virion particles [6,7,13,14], and is the only viral
protein necessary and sufficient for fusion of the viral
envelope membrane with the target host cell [15,16]. The
HRSV F protein is highly conserved (89% amino acid
identity) between subgroups A and B, and shares 81%
amino acid identity with the F protein of bovine respira-
tory syncytial virus (BRSV). The HRSV F protein is synthe-
sized as a 574 amino acid precursor protein designated F0,
which is cleaved at two sites [17-20] within the lumen of
the endoplasmic reticulum removing a short, glycosylated
intervening sequence and generating two subunits desig-
nated F1 and F2 [21]. The mature form of the F protein
present on the surface of the virus and infected cells is
believed to consist of a homotrimer consisting of three
non-covalently associated units of F1 disulfide linked to
F2[22]. As with many other viral fusion proteins, F-medi-
ated fusion with the host cell membrane is believed to be
mediated by insertion of a hydrophobic fusion peptide
into the host cytoplasmic membrane after binding of F
protein to a target receptor on the host cell. Subsequent
conformational changes within F result in the interaction
of heptad repeat (HR) 1 with HR2 and formation of a 6-
helix bundle structure [22-24]. This process brings the
viral and host cell membranes in close proximity resulting
in fusion pore formation, lipid mixing, and fusion of the
two membranes. The precise number of F trimers and
identity of target host surface proteins or molecules
required to mediate fusion are currently unknown.
Although initially isolated from a chimpanzee, humans
are the primary natural host for HRSV. HRSV will only
infect the apical surface of human ciliated lung epithelial
cells, and only fully differentiated human bronchial epi-
thelial cells are permissive for HRSV growth [25]. Dissem-
ination of HRSV to other organs is not observed even in
immunocompromised individuals. Similarly, dissemi-
nated infection with bovine RSV is not observed in
infected cattle. In contrast, in vitro infection of multiple
human cell types other than those derived from lung [26],
cells derived from other animal species, and HRSV infec-
tion of several animal species has been reported [27]. This
suggests that the F protein interacts with either highly con-
served host cell surface molecules or can use multiple
mechanisms to mediate fusion. Several previous studies
have shown the importance of cell-surface gly-
cosaminoglycans (GAGs) [28-32], in particular iduronic
acid, in mediating HRSV infection in vitro [33]; however,
GAG independent, F-mediated attachment pathways have
been described [13]. In a study comparing the host range
of bovine and human respiratory syncytial viruses for cells
derived from their respective natural hosts, species specif-
icity mapped to the F2 subunit [10]. These finding allude
to the existence of host specific receptor molecules that
specifically interact with the F protein to mediate cell
fusion.
To better understand the factors governing host range, we
developed a HRSV F-based quantitative cell fusion assay
and specifically examined the ability of HRSV F protein to
mediate fusion with cells derived from a wide range of
animal species. As cell permissiveness for virus growth is
dependent upon multiple steps, we went on to further
characterize the permissiveness of these cells for viral
mRNA transcription by using a recombinant HRSV engi-
neered to express GFP [33]. The relevance of these find-
ings to the natural course of HRSV disease is discussed.
Methods
Cells and viruses
All cell lines were obtained from the American Type Cul-
ture Collection (ATCC) (Manassas, VA) and were grown at
37°C in a humidified atmosphere of 5% CO2 with the
exception of XLK-WG (grown at 32°C). BHK-21, E. Derm,
HeLa, HEp-2, LLC-PK1, MDBK, MDCK, Mv1Lu, RK-13,
Tb1Lu, Vero and A549 cells (ATCC CCL-10, CCL-57, CCL-
2, CCL-23, CL-101, CCL-22, CCL-34, CCL-64, CCL-37,
CCL-88, CCL-81, and CCL-185 respectively) were main-
tained in modified Eagle media (MEM) with 2 mM L-
glutamine and Earle's balanced salt solution (BSS)
adjusted to contain 1.5 g/L sodium bicarbonate, 0.1 mM
non-essential amino acids, 1.0 mM sodium pyruvate and
10% heat-inactivated, gamma-irradiated fetal bovine
serum (FBS) (HyClone Laboratories, Salt Lake City,
Utah). AK-D cells (CCL-150) were maintained in Ham's
F-12K media containing 10% FBS. NCI-H292 (CRL-
1848), MT-4 and XLK-WG (CRL-2527) cells were main-
tained in RPMI 1640 medium with 2 mM L-glutamine
adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L
glucose, 10 mM HEPES, 1.0 mM sodium pyruvate and
10% FBS. NIH/3T3, QT6 and 293T cells (CRL-1658, CRL-
1708, and CRL-1573) were maintained in Dulbecco's
modified Eagle media (DMEM) with 4 mM L-glutamine
adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L
glucose and 10% FBS. Cell lines were maintained at sub-
confluence and used for only up to 15 passages after
receiving initial stocks from the ATCC. Cell lines were
tested and confirmed to be free of mycoplasma contami-
nation. Human RSV (subgroup A, Long strain, ATCC VR-
26) was obtained from the ATCC. Virus stocks were pre-
pared by infecting HEp-2 cells with RSV at a multiplicity
of infection (MOI) of 0.01 plaque-forming units (PFU)Virology Journal 2005, 2:54 http://www.virologyj.com/content/2/1/54
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per cell. When cytopathic effect (CPE) was evident (~6
days post infection), the culture supernatant was collected
and pooled with the supernatant from the infected cell
pellet, which had been subjected to one freeze-thaw cycle.
The pooled supernatants were maintained on ice,
adjusted to 10% sucrose, flash frozen in liquid nitrogen
and stored in liquid nitrogen. RSV titers were determined
by plaque assay on HEp-2 cells. Serial dilutions of virus
stock were added to monolayers of HEp-2 cells at 80%
confluence and allowed to adsorb for 2 hours at 37°C.
The virus inoculum was then removed, and cells were
overlayed with media containing 0.5% methylcellulose.
After plaques became apparent (5–6 days after infection),
cell monolayers were fixed and stained with 0.5% crystal
violet in 70% methanol, and plaques were counted. HRSV
stock titers were typically >106 PFU/ml and remained sta-
ble for 6 months without loss of titer. A recombinant RSV
rgRSV(224) engineered to express GFP has been previ-
ously described [33]. Stocks of rgRSV(224) were prepared
as described above. Cell lines were infected with
rgRSV(224) at a MOI of 0.1 and infection was visualized
by fluorescent microscopy by monitoring fluorescence at
488 nm at 20, 48, and 120 hours post infection.
Plasmids
A DNA fragment encoding HRSV F protein derived from a
known infectious cDNA sequence for subgroup A, A2
strain, [34] was synthesized with optimal codon usage for
expression in mammalian cells and all potential polyade-
nylation sites (AATAAA) and splice donor sites (AGGT)
removed essentially as described [15]. A similar construct
was designed and synthesized for the B subgroup F pro-
tein (18537 strain, based upon GenBank accession
number D00344). Sequence data is available from the
authors upon request. Restriction sites for XbaI and
BamHI were added to the 5' and 3' ends of the fragments
respectively. The codon optimized HRSV-F DNA frag-
ments (A2 and 18537 strains) were then cloned into the
XbaI and BamHI sites of pcDNA 3.1 (Invitrogen, Inc.,
Carlsbad, CA) to generate pHRSVFOptA2 and
pHRSVFOpt18537. The QuikChange® Site-Directed Muta-
genesis kit (Stratagene®, La Jolla, CA) was used to change
leucine 138 in the fusion peptide region of the F protein
to an arginine (pL138R) in pHRSVFOptA2. Plasmids
pBD-NFκB encoding the activation domain of NFκB fused
to the GAL4 DNA binding domain under the control of
the human cytomegalovirus (HCMV) promoter and pFR-
Luc containing the luciferase reporter gene under the con-
trol of a minimal promoter containing five GAL4 DNA
binding sites were obtained from Stratagene®. pGL3-con-
trol vector encodes a modified firefly luciferase under the
control of the SV40 early promoter (Promega, Inc.). Plas-
mid pVPack-VSV-G encodes the G protein of vesicular sto-
matitis virus (Stratagene®, La Jolla, CA).
Transfections
Cells were transiently transfected using FuGENE 6 reagent
(Roche Applied Science, IN) according to the manufac-
turer's recommendations. Briefly, 7.5 × 105 cells were
plated in 6-well plates and grown overnight to ~90% con-
fluence. Two micrograms of plasmid DNA was complexed
with 6 µl of FuGENE 6 reagent for 30 minutes at room
temperature in 100 µl of serum-free medium. The com-
plex was then added to the cells and incubated at 37°C for
20–24 hours.
Metabolic labeling and immunoprecipitation
293T cells were plated the day before transfection in 6-
well plates at a density of 0.75 × 106 cells/well in DMEM
supplemented with 10% FBS. Cells in 6-well plates were
transfected with a total of 2 µgs of plasmid DNA as
described above. At 20 hours post-transfection, cells were
starved by incubation in DMEM without L-methionine
and L-cysteine containing 5% dialyzed FBS for 45 min-
utes. Cells were then labeled by incubation in DMEM
without L-methionine and L-cysteine containing 5% dia-
lyzed FBS and Redivue Pro-mix in vitro cell labeling mix
containing (100 µCi/ml, 1.5 mls./well) [35S]-methionine
and [35S]-cysteine (Amersham Biosciences, Piscataway,
New Jersey) for 4 hrs. Media was removed, and cells were
harvested and washed in 1 ml 1X phosphate-buffered
saline (PBS) and then lysed with 0.5 mls. of lysis buffer
(50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5% sodium
deoxycholate, 1% IGEPAL (Sigma, St. Louis, MO) and
Complete ™ protease inhibitor cocktail with EDTA (Roche
Biochemicals, Indianapolis, IN). Lysates were spun for 30
minutes at 4°C to remove insoluble material and immu-
noprecipitated by incubation with a saturating amount
(as determined by prior titration) of a cocktail containing
1.5 µgs of anti-F mAbs and protein-A agarose beads (Inv-
itrogen, Inc., Carlsbad CA) overnight at 4?C. Immunopre-
cipitated complexes were washed three times in lysis
buffer and suspended in 20 µl of 4X LDS NuPage loading
buffer with reducing agent and resolved by electrophore-
sis through SDS-containing polyacrylamide gels (SDS-
PAGE) under reducing conditions on a NuPage 4–12%
Bis-Tris polyacrylamide gel (Invitrogen, Inc., Carlsbad
CA). Gels were dried under vacuum for one hour at 80°C
followed by autoradiography.
Flow cytometry
To confirm cell surface expression of HRSV F, 293T cells
were transfected in 6-well plates as described above for
metabolic labeling. Cells were stained with palivizumab
(Synagis ®, IgG1κ) at 1 µg/ml in conjunction with an anti-
human IgG-Alexa-Fluor-488 conjugated secondary
(Molecular Probes, Eugene, OR) at 1 µg/ml in 1X PBS with
2% FBS for analysis with the FACSCalibur (BD Biso-
ciences, CA) by setting a live cell gate in the FSC/SSC plot
and determining the mean fluorescence intensity in theVirology Journal 2005, 2:54 http://www.virologyj.com/content/2/1/54
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FL1 channel. Data analysis was performed with Cell Quest
and FloJo Analysis Software.
Cell fusion assays
293T cells were co-transfected with pHRSVFOptA2 and
pBD-NFκB (effectors cells), and the panel of cell lines
from a variety of different species were transfected using
FuGene-6 (Roche Biochemicals, Inc.) with the pFR-Luc
reporter plasmid (reporter cells) using conditions
described above. Alternatively, 293T cells were co-trans-
fected with pHRSVFOptA2 and pFR-Luc, and the panel of
cell lines from a variety of different species were trans-
fected with the pBD-NFκB reporter plasmid. A plasmid
encoding the vesicular stomatitis virus (VSV) G protein
linked to the HCMV promoter (pVPack-VSV-G) was used
as a positive viral fusion protein control. At 24 hours post
transfection, unless otherwise specified, 3 × 104 of the
transfected 293T (effector cells) were mixed with an equal
amount of the various other transfected cells (target cells)
in a 96-well plate and incubated an additional 24 hours
prior to measurement of luciferase activity using the
Steady Glo Luciferase reporter system (Promega, Inc.).
The various cell lines were transfected with pGL3-control
to determine relative differences in transfection efficien-
cies and cell-type specific expression of luciferase. To fur-
ther normalize, a single preparation of effector cells was
used per each experiment on the various reporter cell
preparations. Cells individually transfected with the F
expression plasmids, pBD-NFκB or pFR-Luc individually
were used as negative controls.
Results
Expression of RSV F protein
We designed and synthesized a cassette encoding the full-
length HRSV-F gene (A2 strain and 18537 strains) in
which codon usage was optimized for mammalian expres-
sion and all potential splice-donor sites and polyadenyla-
tion sites were removed similar to a previous report [15].
Upon transient transfection of 293T cells with this plas-
mid expressing this optimized HRSV F protein sequence
under the control of a human cytomegalovirus immediate
early promoter (pHRSVFoptA2), giant multinucleated
cells (syncytia) were readily apparent within 24 hours
post transfection (Figure 1A). The amount of syncytia
qualitatively increased throughout the culture for up to 72
hours, after which extensive cell death and sloughing was
observed. This syncytia is phenotypically indistiguishable
from that observed following infection of 293T cells with
HRSV in tissue culture (data not shown). To confirm
appropriate processing of the F protein, 293T cells were
transfected with plasmids expressing HRSV F derived from
subgroup A (A2 strain) or subgroup B (18537 strain) and
metabolically labeled followed by immunoprecipitation
of lysates with HRSV F-specific monoclonal antibodies. As
a control, 293T cells were infected with HRSV (Long
strain). As shown in Figure 1B, immunoprecipitation
demonstrates the presence of the unprocessed full length
F0 species migrating at approximately 70 kDa, and the
processed F1 and F2 fragments of ~50 kDa and 20 kDa,
respectively, identical to the F protein immunoprecipi-
tated from HRSV infected 293T cells. The multiple bands
observed in the region of 20 kDa likely represent the
incompletely processed F2 (F2+), different glycosylated
forms of F2, or a combination of both [21]. The band
present migrating more rapidly than F1 (~35 kDa) most
likely represents a cellular protein as this band was
observed in lysates derived from untransfected and con-
trol vector transfected cells with varying intensity unre-
lated to the level of HRSV F expressed (see Figure 2B, lanes
3 and 4). Similar levels of expression were observed for
the HRSV F protein from the A and B subgroups (Figure
1B, lane 3 compared to lane 4). Furthermore, the level of
F protein expression in the transfected cells was greater at
24 hours post transfection than in HRSV-infected cells at
24 hours post infection (Figure 1B, lane 5). Flow cytome-
try confirmed abundant cell surface expression of HRSV F
protein (Figure 1C).
HRSV F protein fusion assay
To measure the ability of the HRSV F protein to mediate
cell fusion across various cell lines, we developed a quan-
titative fusion assay. Specifically, 293T cells were co-trans-
fected with plasmids encoding the optimized HRSV F
protein and a transcriptional transactivator fusion protein
consisting of the GAL4 DNA-binding domain fused to the
activation domain of NFκB. These effector cells were
mixed with a separate set of reporter cells that were trans-
fected with a reporter plasmid containing the luciferase
gene under the control of a GAL4 responsive promoter.
HRSV F mediated cell fusion of the two cell populations
results in co-localization of the GAL4-NFκB transactivator
fusion protein with the GAL4 responsive luciferase
reporter plasmid and subsequent transcriptional transac-
tivation of the reporter gene. A dilution series from 50,000
to 100 effector cells were added to a fixed amount of
reporter cells (50,000), and luciferase activity was moni-
tored 24 hours later. As a control to determine the maxi-
mum signal, cells were co-transfected with the reporter
and activator plasmids (pFR-Luc + pBD-NFκB). As shown
in figure 2A, luciferase activity was absent in cells trans-
fected with either reporter or activator plasmids alone.
Additionally, mixing of cells which had been separately
transfected with the reporter or activator plasmids did not
produce detectable luciferase activity indicating no spon-
taneous cell fusion (data not shown). However, mixing an
increasing number of cells that had been co-transfected
with the GAL4-sensitive reporter plasmid and HRSV F
expressing plasmid with those that had been transfected
with the GAL-NFκB activator plasmid resulted in a dose-
dependent increase in luciferase activity (Figure 2A),Virology Journal 2005, 2:54 http://www.virologyj.com/content/2/1/54
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indicating fusion of the two cell populations. The maxi-
mum signal observed from mixing the effector and
reporter populations was similar to the signal obtained
when the activator and reporter plasmids were co-trans-
fected into the same cells.
To determine if this property was restricted to the F pro-
tein derived from a single strain or subgroup, 293T cells
co-transfected with a plasmid encoding the HRSV F pro-
tein derived from either subgroup A (A2 strain) or B
(18537 strain) together with a plasmid encoding the
GAL4-NFκB transactivator fusion protein (effector cells)
were then mixed 24 hours later with an equal amount of
a separate population of 293T cells (reporter cells) which
had been transfected with the GAL4 responsive reporter
plasmid. As shown in Figure 2B, the F protein of either
HRSV subgroup A and B mediated cell-cell fusion as meas-
ured by the increased luciferase activity relative to the neg-
ative control (GAL4-NFκB transactivator fusion protein
only). The fusion activity of the F protein derived from the
A2 strain was approximately 2-fold higher than that
observed with the 18537 strain despite similar expression
levels. Whether this finding reflects differences in the
pathogenicity between these two isolates is unknown,
although a recent study suggests similar pathogenicity for
both subgroups [35]. To further confirm that the observed
A) Syncytia formation by RSV-F DNA in transfected cells Figure 1
A) Syncytia formation by RSV-F DNA in transfected cells. 293T cells were mock transfected or transfected with 
pHRSVFOptA2 and visualized by light microscopy 48 hours post transfection. The arrow indicates giant multinucleated cell for-
mation. B) Processing of RSV F in transfected cells. 293T cells were either mock transfected (lane 1), transfected with pCMV-
β-gal (lane 2), transfected with pHRSVFOptA2 (lane 3), pHRSVFOptB18537 (lane 4), or infected with RSV (Long strain, MOI = 
1) for 24 hours followed by metabolic labeling for 6 hours with [35S]-cysteine/methionine. Labeled cell lysates were immuno-
precipitated with HRSV F specific mAbs, and immunoprecipitates were resolved by SDS-PAGE as described in methods. C) 
Cell surface expression of RSV F in transfected cells. 293T cells were either mock transfected or transfected with 
pHRSVFOptA2 for 24 hours followed by flow cytometry using HRSV F specific monoclonal antibodies as described in methods.
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fusion activity was inherent to the HRSV F protein, a point
mutation (L138R) was generated in the fusion peptide
consensus sequence within the fusion peptide region.
Mutation of leucine residue 138 to arginine reduced
fusion activity to 10% relative to wild-type (Figure 3A).
Despite the fact that this mutant appeared to produce
somewhat lower levels of fully processed F protein (Figure
3B, lane 2) for unknown reasons, this mutant was
expressed at high levels on the cell surface (Figure 3C)
indicating that the cell fusion observed was attributable to
the HRSV F protein.
Host range of HRSV-mediated fusion
To determine the host range of HRSV F mediated fusion
using the quantitative fusion assay. 293T effector cells
were prepared as described above. As we previously dem-
onstrated proper protein processing, abundant cell surface
expression of HRSV F protein and cell fusion activity using
A) Dose dependent fusion activity of HRSV F derived Figure 2
A) Dose dependent fusion activity of HRSV F derived. 293T cells were transfected with either pFR-Luc alone (■ ), pBD-NFκB 
alone (▲ ), co-transfected with pFR-Luc and pBD-NFκB (▼ ), or co-transfected with pHRSVFOptA2 and pBD-NFκB and mixed 
24 hours after transfection in various amounts with cells that had been transfected with pFR-Luc alone (◆ ). Luciferase activity 
was measured 24 hours post mixing as described in methods and is reported as relative light units. B) Fusion activity of HRSV 
F derived from subgroups A and B. 293T cells co-transfected with pBD-NFκB and either pHRSVFOptA2, pHRSVFOptB18537, 
or vector only (NFκB only). Cells were mixed 24 hours later with a separate population of 293T cells transfected with pFR-
Luc, and luciferase activity was measured 24 hours post mixing as described in methods. Luciferase activity is reported as rela-
tive light units.
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293T cells, we selected these as our effector cells. These
effector cells were mixed with reporter cells derived from
a diverse range of species (Table 1) that were transfected
with the GAL4-responsive reporter plasmid. To account
for any differences in relative transfection efficiencies and
expression of the luciferase reporter among the various
target cells lines, the target cell lines were transfected with
a plasmid containing the luciferase gene under the control
of the SV40 early promoter (pGL3-control), and relative
luciferase activity was measured. To account for potential
differences in host cell transcription factors that mediate
activation of the reporter plasmid, the assay was flipped
and 293T cells were co-transfected with the HRSV F
expression plasmid and the GAL4 responsive reporter
plasmid, and the cells from the various species were trans-
fected with the GAL4-NFκB transactivator fusion protein
A) Comparison of fusion activity of wild-type and a fusion peptide mutant of HRSV F Figure 3
A) Comparison of fusion activity of wild-type and a fusion peptide mutant of HRSV F. 293T cells co-transfected with pBD-
NFκB and either pHRSVFOptA2 or pL138R were mixed 24 hours later with a separate population of 293T cells that had been 
transfected with pFR-Luc, and luciferase activity was measured 24 hours post mixing as described in methods. Luciferase activ-
ity is reported as relative light units. B) Processing of the wild-type and L138R mutant of HRSV F was determined by metabolic 
labeling 293T cells transfected with either pHRSVFOptA2 (lane 1), pL138R (lane 2), pCMV-β-gal (lane 3), or mock transfected 
(lane 4) for 6 hours with [35S]-cysteine/methionine followed by immunoprecipitation of lysates with HRSV F specific mAbs, and 
analysis of immunoprecipitates by SDS-PAGE as described in methods. C) Cell surface expression of the wild-type and L138R 
mutant F proteins in 293T cells transfected with either pHRSVFOptA2 or pL138R was compared by flow cytometry as 
described in methods.
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plasmid. For further comparison, we used the VSV G pro-
tein, which is known to mediate entry into cells derived
from a wide range of species.
As shown in figure 4, despite a limited host range in
nature, HRSV F was able to mediate fusion to various
degrees with cells derived from all species examined. This
fusion activity was within 5-fold of the fusion activity
mediated by the VSV G protein in the cell types tested
here. Generally, there was little qualitative difference
between results obtained when either the reporter plas-
mid or the activator plasmid were co-transfected with the
F expression plasmid (compare figures 4A and 4B with fig-
ures 4C and 4D). As expected, the relative transfection
efficiencies of the various cell lines as measured by the
luciferase activity from the plasmid pGL3-control varied;
however, there was no direct correlation between transfec-
tion efficiencies and fusion activity. For example, cell lines
such as BHK-21 and LLC-PK1 cells which transfected well,
had lower relative levels of fusion. In contrast, cell lines
such as MT-4, MDCK and XLK-WG which had low trans-
fection efficiency, had appreciable levels of HRSV F medi-
ated fusion. These findings support the hypothesis that
HRSV F protein interacts with evolutionarily conserved
host cell surface molecules or can use multiple mecha-
nisms to enter cells.
Infections using recombinant HRSV expressing GFP
The results obtained from the fusion assays indicated that
HRSV F is able to mediate fusion with cells from multiple
diverse species, suggesting that virus entry is not the pri-
mary determinant of host range. To examine whether viral
mRNA transcription had occurred, the various cell lines
were infected with a recombinant HRSV (rgRSV224)
expressing GFP [33] and fluorescence scored at 20, 48,
and 120 hours post infection. As expected, rgRSV(224)
infection of human (HEp-2, HeLa, A549) and animal
(Vero, Mv1Lu, MDBK) [36-39] cell lines commonly used
to propagate HRSV resulted in a time dependent increase
in the number of cells expressing GFP (≥50% by day 5) as
seen by fluorescent microscopy indicating spread of infec-
tion throughout the culture (Figure 5). Infection of other
human cell lines such as NCI-H292 [40], and 293T also
resulted in a time dependent increase in the number of
cells expressing GFP. Infection of hamster BHK-21 cells
also resulted in a time dependent increase in the number
of GFP positive cells, although the appearance of a large
number of bright GFP positive cells seemed delayed.
Interestingly, hamsters are considered to be a semi-per-
missive host for HRSV [27,41] and produce lung titers
similar to those achieved in mice. Whether this reflects a
tissue-specific phenomenon (kidney versus lung) remains
to be determined. Infection of cell lines (Tb1Lu, AK-D, E.
Derm, NIH/3T3, LLC-PK1, and XLG-WG) derived from
other species (bat, cat, horse, mouse, and frog respec-
tively) produced few or occasional GFP expressing cells
over the course of the five-day infection. The number of
positive cells did not increase over time, and in some cases
(AK-D cells) appeared to decrease. Aside from mice, infec-
tion in vivo of these other species by HRSV has not been
described. This finding also supports the finding that high
titers of virus (>105 PFU) are typically required to initiate
infection in mice after intranasal inoculation, and that rel-
atively few cells become viral antigen positive.
Discussion
We have developed a quantitative reporter gene based
cell-cell fusion assay for HRSV F. Prior assays have been
based upon visual counting of plaques or syncytia after
staining of infected monolayers, or infection another virus
such as vaccinia, to provide HRSV F protein, which could
potentially complicate interpretation. The assay described
herein is a means of quantifying the fusion activity of the
HRSV F protein. This assay has multiple applications. For
example, this assay can be used as a means of studying the
structure-function of the HRSV F protein, or for evaluating
the activity of mutations in the F protein without the need
to select for antibody or compound escape mutants or
generate point mutations in a reverse genetics system. We
propose that this assay also has utility in the identification
and characterization of inhibitors of HRSV entry for the
development of specific agents to prevent and treat HRSV
infections. We have used this assay as a means of
exploring the host-range of HRSV and have shown that
the HRSV F protein is able to mediate fusion with cells
derived from a wide range of vertebrate species.
Table 1: Species and tissue origin of cell lines used in this study 
are listed.
Cell line Species, tissue
XLK-WG Xenopus laevis (S. African clawed frog), kidney
QT6 Coturnix coturnix japonica (Japanese quail), fibrosarcoma
Tb1Lu Tadarida brasiliensis (free-tailed bat), lung
NIH/3T3 Mus musculus (mouse), fibroblast
BHK-21 Mesocricetus auratus (Syrian golden hamster), kidney
RK-13 Oryctolagus cuniculus (rabbit), kidney
LLC-PK1 Sus scrofa (pig), kidney
Mv1Lu Musteal vison (mink), lung
AK-D Felis catus (domestic cat), fetal epithelial
MDCK Canis familiaris (domestic dog), kidney
MDBK Bos taurus (cow), kidney
E. Derm Equus caballus (horse), dermal
Vero Cercopithecus aethiops (African green monkey), kidney
HEp-2 Homo sapiens (human), laryngeal carcinoma
HeLa Homo sapiens (human), cervical carcinoma
MT-4 Homo sapiens (human), T-cell
293T Homo sapiens (human), kidney
NCI-H292 Homo sapiens (human), epidermoid pulmonary carcinoma
A549 Homo sapiens (human), lungVirology Journal 2005, 2:54 http://www.virologyj.com/content/2/1/54
Page 9 of 12
(page number not for citation purposes)
Cell lines known to be permissive for HRSV growth such
as HEp-2, HeLa, A549, Vero, MDBK, and Mv1Lu were
highly competent for F protein fusion as expected. Some-
what surprisingly, a wide variety of cells derived from spe-
cies not known to be normally infected by HRSV were also
capable of undergoing HRSV F protein mediated fusion.
Most surprising were the results obtained using the XLK-
WG cells which are derived from the amphibian Xenopus
laevis. Although this finding implies that HRSV virion is
able to enter a wide range of cells, the results of the infec-
tion studies using the GFP-expressing RSV indicate that
viral mRNA transcription seems limited in cell lines
derived from certain species. Taken together these results
suggest that events post-viral entry are the primary deter-
minants that mediate the host range of HRSV. During
natural infection of humans, viral replication is restricted
to epithelial cells of the upper and lower respiratory tract.
Although limited HRSV replication within human alveo-
lar macrophages and detection of HRSV sequences in
peripheral blood monocytes (PBMCs) has also been
reported [42,43], dissemination of HRSV to other organs
is not observed even in immunocompromised individu-
Fusion activity of HRSV F with cell lines derived from various species Figure 4
Fusion activity of HRSV F with cell lines derived from various species. Cell lines derived from various species (target cells) were 
either transfected with pFR-Luc and mixed 24 hours later with 293T cells that had been co-transfected for 24 hours with 
pHRSVFOptA2 or pVPack-VSV-G and pBD-NFκB (Figs. 4A and 4B), or the target cells were transfected with pBD-NFκB and 
mixed 24 hours later with 293T cells that had been co-transfected for 24 hours with pHRSVFOptA2 or pVPack-VSV-G 
together with pFR-Luc (Figs. 4C and 4D). Cell lines derived from various species were transfected with either pFR-Luc or pBD-
NFκB only as negative controls. Luciferase activity was measured 24 hours post mixing of the cell populations as described in 
methods and is reported as relative light units.
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als. Similarly, disseminated infection with bovine RSV is
not observed in infected cattle [44]. Given the ability of
the HRSV F protein to mediate fusion with cells derived
from a diverse range of vertebrate species, the implication
is that HRSV may not be able to access these sites or
undergoes non-productive infection in many cell types
other than epithelial cells of the respiratory tract.
Although the overall biological significance of such an
abortive infection is unclear, biological effects of the indi-
vidual HRSV proteins have been reported.
HRSV F protein has also been shown to be a ligand for
TLR4, and HRSV infection persists longer in TLR4-/- defi-
cient mice [45,46]. HRSV F protein also binds surfactant
proteins A and D (SP-A and SP-D) [47,48], although the
implications of these findings in human infection are
unclear. G protein has been shown to modulate multiple
immune related activities. Soluble G suppresses some
PBMC and lung CD8+ T-cell effector and peripheral mem-
ory responses [49], induces chemotaxis, eosinophilia, and
both soluble and membrane forms of G bind the fractalk-
ine receptor, CX3CRI [50]. Additionally, G has a domain
with similarity to the TNF-α receptor (p55), although it
has not been directly shown to be a TNFR antagonist.
Additionally, G has been shown to modify CC and CXC
chemokine mRNA expression [50], and suppress lympho-
proliferative responses to antigens in PBMCs [51].
It is tempting to speculate that entry of HRSV into cell
types other than those permissive for complete virus
growth may be a strategy by which the virus is able to
modulate immune responses while avoiding the induc-
tion of antiviral responses such as the interferon (IFN)
pathway by production of double-stranded RNA replica-
tion intermediates in these cells. Limited viral mRNA tran-
scription in the absence of virus RNA replication would
result in expression of NS1 and NS2 which have been
shown to block the IFN response [52] possibly preventing
these unproductively infected cells from responding to
external cytokines such as IFNs. Such a strategy may help
explain why despite little antigenic drift in the F protein,
infection by HRSV infection only confers partial protec-
tion, with reinfections occurring throughout life [53-55].
As the fusion proteins of other members of the Paramyxo-
viridae family, such as Hendra virus [56], are also able to
mediate fusion with a wide variety of cells derived from
multiple species, it is possible that such a strategy is shared
by other members of this virus family.
Infection of various cell lines by rg224(RSV) Figure 5
Infection of various cell lines by rg224(RSV). Cell lines derived from various species were infected with rgRSV(224) at an MOI 
= 0.1 and GFP-expressing cells were visualized at 20, 48, and 120 hours post infection by fluorescent microscopy by monitoring 
fluorescence at 488 nm.Virology Journal 2005, 2:54 http://www.virologyj.com/content/2/1/54
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